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64S Abstracts June Supplement 2014Objectives: The aim of this study was to evaluate the
impact of smoking cessation on the progression of throm-
boangiitis obliterans (Buerger’s disease). The impact of
various comorbidities on limb amputation was also
evaluated.
Methods: A retrospective analysis of the cross-
sectional National Inpatient Sample (2000-2011) was
used to identify patients with a diagnosis of Buerger’s
disease (International Classiﬁcation of Diseases, Ninth
Revision, 44.31). Patients who underwent extremity
amputation were characterized according to smoking
status and comorbidities, including renal failure, diabetes,
coagulopathy, hypertension, heart disease, and chronic
obstructive pulmonary disease, and compared with
those who did not undergo amputation. Odds ratios
were calculated for all statistically signiﬁcant (P < .05) dif-
ferences identiﬁed using the Fisher exact test and Student
t-test.
Results: A total of 4,489 patients with Buerger’s
disease were identiﬁed in the United States between
2000 and 2011, of which 193 (4.3%) underwent limb
amputation. A total of 1908 (42.5%) patients were
smokers. Smoking was slightly more common among
patients who underwent amputation (46.1% vs 42.3%;
P ¼ .30; 95% conﬁdence interval, e0.11 to 0.03). Of
the comorbidities evaluated, renal failure was two times
more common among patients who underwent amputa-
tion (6.2% vs 3.2%; OR, 2; P ¼ .02; 95% conﬁdence
interval, e0.06 to e0.004). Patients who were former
smokers were just as likely to require limb amputation
(9.3% vs 11.5%; P ¼ .35).
Conclusions: Although the association between
smoking and Buerger’s disease is well understood,
whether smoking leads to the limb amputation from
this disease is unclear. This study demonstrates that the
primary factor associated with limb amputation
from Buerger’s disease is end-stage renal disease, not
smoking. Further, smoking cessation does not appear to
prevent progression to limb amputation in Buerger’s
disease.
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Vascular Surgeons Can Improve the Cardiovascular
Health of Patients With Clinical Atherosclerotic
Cardiovascular Disease by Implementing an Intensive
Lipid-Lowering Regimen and Providing Smoke
Cessation Counseling
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Mattera1, Joseph D. Raffetto1, Deepak L. Bhatt3, John
M. Gaziano1, James T. McPhee1. 1VA Boston Health
System, Boston, Mass; 2Boston Medical Center, Boston,
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Objectives: To assess the impact of a vascular surgery-
led program to improve the cardiovascular risk of patients
with clinical atherosclerotic cardiovascular disease
(ASCVD) by implementing an intensive lipid-lowering
regimen and providing smoke cessation counseling.
Methods: The records of all patients seen in a single-
center vascular surgery clinic over a 1-month period inNovember 2013 were retrospectively reviewed till October
1, 2011, when the vascular surgery service implemented a
cardiovascular risk reduction program in patients with clin-
ical ASCVD.
Results: Included were 144 consecutive patients with
a median follow-up of 315 days (range, 0-740 days). Pre-
intervention, the baseline median low-density lipoprotein
(LDL) was 86 mg/dL (range, 39-197 mg/dL) and 96 pa-
tients (71.1%) had an LDL >70 mg/dL. Fifty-two patients
(37%) were current smokers, 41 (71%) smoked heavily
(more than one pack per day). Fifty-ﬁve percent of patients
had documentation that this intervention was administered
at the initial vascular surgery encounter after this program
was started. The mean lag time to the ﬁrst vascular surgery
encounter with intervention documentation was 117 days
(median, 0 days; range 0-721 days). At the latest follow-
up, 92 (72%) of the encounters by a vascular surgeon docu-
mented that the intervention was administered, ﬁnal
median LDL was 79 mg/dL (range, 31-198 mg/dL), 80
patients (62%) had an LDL >70 mg/dL, and 60 patients
(47.2%) had a decrease in their LDL. Patients that had
no observed decrease in their LDL had a signiﬁcantly lower
mean level at baseline (82.3; standard deviation, 28.7;
range 39-197 mg/dL) compared with those with an
observed decrease in LDL (mean, 98.8; standard deviation,
32.8; range, 42-187 mg/dL; P ¼ .003). At the latest
follow-up, 41 patients (31.5%) were currently smoking,
21 (43.7%) of whom smoked heavily (more than one
pack per day).
Conclusions: Vascular surgeons can improve the car-
diovascular health of their patients by implementing a pro-
gram of intensive lipid control and smoking cessation in
patients with clinical ASCVD. Further studies are needed
to determine the impact on cardiovascular event rates.
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Deﬁning and Reporting Academic Activity: The
Academic RVU Can Justify the Mission
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Objectives: The academic mission is under strain.
Although clinical activity is easily quantiﬁed by the Relative
Value Units (RVU), there are multiple ad hoc measures of
academic activity. This study reports the use of academic
RVU (aRVU) derived for all nonclinical activities to justify
nonclinical protected time of individual faculty, prioritize
divisional activities, and drive the academic.
Methods: All nonclinical activity for divisional faculty
were correlated and subjected to a deﬁned scoring sys-
tem. The system was set up in ﬁve modules (publica-
tions, presentation, clinical trial, grants educational,
administration and community). Each module was
